Company Overview
Cellebrite DI Ltd. develops software and services for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company provides a platform of software solutions used to access, collect, review, extract, decode, decrypt, analyze, share and manage digital evidence across the investigative lifecycle for a range of investigations, such as child exploitation, homicide, anti-terror, border control, sexual crimes, organized crime, human trafficking, corporate security, and intellectual property theft, as well as financial crimes, including those involving cryptocurrency. It also offers Inseyets, digital forensics software that collects and reviews digital evidence from various digital sources when conducting legally sanctioned investigations; Guardian Forensics, an evidence management solution which enables customers to manage their digital forensics workflows, and to store, share and review digital evidence; Guardian Collaborate, a digital evidence sharing tool; and Guardian Investigate, a case management and AI-powered analytics solution. In addition, it provides Cellebrite Pathfinder, which reduces the time spent manually reviewing digital evidence and enables actionable insights into a range of crime types; Corellium Falcon for conducting mobile vulnerability research, exploit introspection, and malware analysis; and Corellium Viper for mobile application penetration testing capabilities. Further, the company offers professional services, such as training and certification services, and advanced services. It serves federal, state, and local agencies, as well as corporations and service providers. The company is headquartered in Petah Tikva, Israel.
Why Investors Should Care
Revenue has grown at a 20.7% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $475.68M (+18.6% YoY); net profit $78.33M.
- Trailing 12 Months Year-on-year growth — revenue +15.8%, earnings -67.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 20.7%, profit CAGR -13.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 20.68% |
| 1 Year: | 15.80% |
Compounded Profit Growth
| 5 Years: | -13.45% |
| 1 Year: | -67.90% |
Stock Price Performance
| 1 Year: | -18.16% |
| 6 Months: | -23.31% |
| 3 Months: | -14.74% |
| 1 Month: | -28.48% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)39.49 · Neutral
P/E of 49.78 is above the sector median of 29.22 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 20.7% over 5 years.
- Generates positive free cash flow.
CONS
- Earnings shrank at -13.5% CAGR over 5 years.
- Trading 41.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Technology).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CLBT Cellebrite DI Ltd. TECH | 11.45 | 49.78 | $2.88B | 0.00% | 11.68% | 12.42% | 20.68% | -13.45% |
| 2 | NVDA NVIDIA Corporation NDXSPXR3KAITECH | 225.73 | 28.50 | $5.45T | 0.46% | 74.66% | 117.21% | 24.64% | 32.12% |
| 3 | AAPL Apple Inc. NDXSPXR3KTECH | 316.22 | 36.22 | $4.61T | 0.34% | 68.72% | 148.75% | 1.81% | 3.92% |
| 4 | MSFT Microsoft Corporation NDXSPXR3KAITECH | 493.95 | 27.49 | $3.67T | 0.79% | 26.33% | 34.04% | 9.93% | 11.90% |
| 5 | TSM Taiwan Semiconductor Manufacturing Company Limited AITECH | 439.00 | 32.71 | $2.28T | 0.95% | 30.20% | 39.97% | 18.94% | 19.57% |
| 6 | AVGO Broadcom Inc. NDXSPXR3KAITECH | 368.56 | 46.95 | $1.75T | 0.71% | 16.70% | 44.25% | 17.04% | 54.08% |
| 7 | MU Micron Technology, Inc. NDXSPXR3KAITECH | 1,000.26 | 22.59 | $1.13T | 0.05% | 13.69% | 66.64% | 13.68% | 26.02% |
| 8 | AMD Advanced Micro Devices, Inc. NDXSPXR3KAITECH | 505.74 | 128.36 | $825.61B | 0.00% | 5.47% | 10.20% | 11.81% | 66.28% |
| 9 | ASML ASML Holding N.V. NDXAITECH | 1,764.85 | 59.89 | $677.88B | 0.51% | 42.97% | 53.94% | 15.55% | 19.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 107.55M | 113.28M | 126.03M | 128.82M | 128.30M |
| Cost of Revenue | 17.49M | 17.68M | 20.31M | 19.69M | 22.42M |
| Gross Profit | 90.06M | 95.60M | 105.72M | 109.13M | 105.88M |
| Operating Expenses | 77.79M | 81.18M | 86.72M | 88.33M | 96.76M |
| Operating Income | 12.27M | 14.42M | 18.99M | 20.80M | 9.12M |
| EBITDA | 14.90M | 30.52M | 21.69M | 49.47M | 16.12M |
| Interest Expense | - | - | - | - | - |
| Pretax Income | 19.33M | 20.79M | 24.29M | 26.27M | 13.63M |
| Tax Provision | 1.93M | 1.31M | 4.10M | 5.01M | 2.70M |
| Net Income | 17.40M | 19.48M | 20.19M | 21.26M | 10.94M |
| Diluted EPS | 0.07 | 0.08 | 0.08 | 0.08 | 0.04 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 270.65M | 325.11M | 401.20M | 475.68M |
| Cost of Revenue | - | 50.75M | 53.23M | 62.59M | 75.17M |
| Gross Profit | - | 219.91M | 271.88M | 338.61M | 400.50M |
| Operating Expenses | - | 218.86M | 238.64M | 281.70M | 334.02M |
| Operating Income | - | 1.04M | 33.24M | 56.91M | 66.48M |
| EBITDA | - | 130.10M | -65.41M | -265.35M | 103.07M |
| Interest Expense | - | 149.00K | 141.00K | 29.00K | 523.00K |
| Pretax Income | - | 120.76M | -75.56M | -275.98M | 90.68M |
| Tax Provision | - | -45.00K | 5.54M | 7.02M | 12.35M |
| Net Income | - | 120.81M | -81.10M | -283.01M | 78.33M |
| Diluted EPS | - | 0.59 | -0.43 | -1.35 | 0.31 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 403.29M | 532.88M | 690.57M | 938.85M |
| Current Assets | - | 295.93M | 422.08M | 567.59M | 575.85M |
| Cash & Equivalents | - | 87.64M | 189.52M | 191.66M | 124.46M |
| Inventory | - | 10.18M | 9.94M | 8.94M | 7.60M |
| Receivables | - | 78.76M | 77.27M | 82.36M | 104.97M |
| Total Liabilities | - | 329.43M | 498.67M | 354.55M | 454.53M |
| Current Liabilities | - | 207.78M | 253.82M | 295.50M | 369.66M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 15.36M | 14.13M | 10.97M | 22.67M |
| Total Equity | - | 73.86M | 34.21M | 336.02M | 484.32M |
| Shares Outstanding | - | 193.06M | 203.27M | 234.57M | 248.62M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 20.58M | 102.06M | 132.17M | 173.54M |
| Investing Cash Flow | - | -91.23M | -22.54M | -149.47M | -268.25M |
| Financing Cash Flow | - | 13.97M | 21.77M | 20.65M | 25.05M |
| Capital Expenditure | - | -9.09M | -7.92M | -10.61M | -13.22M |
| Free Cash Flow | - | 11.49M | 94.14M | 121.56M | 160.32M |
| Net Change in Cash | - | -56.68M | 101.28M | 3.35M | -69.65M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 81.3% | 83.6% | 84.4% | 84.2% |
| Operating Margin % | - | 0.4% | 10.2% | 14.2% | 14.0% |
| Net Margin % | - | 44.6% | -24.9% | -70.5% | 16.5% |
| ROE % | - | 163.5% | -237.1% | -84.2% | 16.2% |
| ROCE % | - | 0.5% | 11.9% | 14.4% | 11.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | True Wind Capital Management, L.P. | 5.56% | 13.86M | $161.06M |
| 2 | Voss Capital, LP | 4.59% | 11.44M | $132.95M |
| 3 | Pertento Partners LLP | 3.21% | 8.00M | $93.02M |
| 4 | Phoenix Financial Ltd. | 2.48% | 6.18M | $71.83M |
| 5 | FMR, LLC | 2.39% | 5.97M | $69.39M |
| 6 | Blackrock Inc. | 2.28% | 5.68M | $66.05M |
| 7 | Nine Ten Capital Management LLC | 1.65% | 4.13M | $47.95M |
| 8 | Artisan Partners Limited Partnership | 1.31% | 3.27M | $37.96M |
| 9 | Wellington Management Group, LLP | 1.22% | 3.05M | $35.44M |
| 10 | Clal Insurance Enterprises Holdings Ltd | 1.11% | 2.77M | $32.22M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CLBT
Learn Why The Bull Case For Cellebrite DI (CLBT) Could Change Following Secure Cloud Approval - simplywall.st
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxQeXVOY29aMmNFQkJnUVRwTEdvV0VPWHUzYU1TUUY2UGxuUGpjekxRWnBaZDdaT3QxTWd0Y2tWT05ReTg3MTBLUEI2UUlmMG5fQm1XV0lLWUdGYnJFZHV4SjVOQ1U0UG5wTXdkdFFDT0dnakFHUEVXVnZ3b2NSUHFuejhGYkR2UmpSQUhrbj…
Cellebrite DI Ltd. (CLBT) Securities Investigation Notice - Levi & Korsinsky - PR Newswire
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxPME00ZnNaRjNFSUlNNkNWbDNvRWk4NHRTMktKbmxVU1NTeG9FaTQ5VWJkSXFIWjFzdE9rVk1uN1FSUEY0and1VjdvbFpYd3hHUmszWkNTdzdCaHNfWEtDUFhSZ2Z0WGhkQTN0TmY3N2ZIN0JIaTdFaGRJMC1HVjl0cDN3WEFlajcyX2I3MG…
Cellebrite DI (CLBT) Cuts Guidance And Changes CEO, Is The Stock Now Cheap? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPRmdXc3ptWGZGa3NEb3NWekFvNVhLc1dzLWR0c0VzS3JXZEZ4cjlYUDNPOFhrb0hlUUp2UW9VQnV3VEJXc1hJZlJsMlFGeVpVTzNqd3QzdV9jVF9BYU9nS3g2MTlQRE9tRHNIdGx4REt2TFZtRmFjQzFkTnNRSGpjWlFpYzZJTHNldUxzdk…
When Should You Buy Cellebrite DI Ltd. (NASDAQ:CLBT)? - Moomoo
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxPQUVBbGlUTXd6ZGFtQUtGcmFHeTBobU1zS1ZjWHV2U3pOS2tHT0dDODNXRC1PR0g3SjVicGdndTE1WVE2RjlzUFF5Z3p3d1VKanFrOVhKNC1tTDFJVnJucUd3LWYtOWhrTW1URGctLUZ0SGEyZ0dVbDgxeVZUNWFaR3R6WmtTM3ZleGoxRG…
$CLBT stock is down 31% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxNV0Vqc2ppWW5Iek5JN1VSS0V4N1ZlMmtrVDBycnppazNCcVpmSV9QTnZqeHpCb1d6d0I4R2ZWLVV5Tlh6YzBlZkRpOXUwYVQ2bTUyZW9UcUwtR0tySlVQUlRqRzZmR3E1aUJrOWZVczhHc3lkc0lmbTJXSGFoY3FJZFA0TTBIVmphTXBoTE…
Cellebrite DI (CLBT) advisor sells 25K shares around $11 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxPZVpTdEwxSU5UZXBmdDBJclpoRl9oUHJqZ1pNQ1NubVF0RGk5cmRRUFlSY29SVHFDdHF4WUZONTlQVWJoOUlhX3d5cUNYOHVEOFZ3MXZZeW1QOGVOLUxTVTY0VnBkcEZLZGVDTHhCTUhmSWlZSDJMQXFXVFZteDFVamtDQXdYQS16LTk4RG…
CLBT — Frequently Asked Questions
What is the current share price of Cellebrite DI Ltd. (CLBT)?
As of 2026-09-19 21:16 PDT, Cellebrite DI Ltd. (CLBT) trades at $11.45 on NasdaqGS. Its 52-week range is $10.44 to $19.56.
What is the market capitalisation of CLBT?
Cellebrite DI Ltd. (CLBT) has a market capitalisation of $2.88B on NasdaqGS.
What is the P/E ratio of CLBT?
CLBT trades at a trailing price-to-earnings (P/E) ratio of 49.78. The industry average P/E is 29.22. Its price-to-book (P/B) ratio is 5.33.
What is the return on equity (ROE) of CLBT?
CLBT has a return on equity (ROE) of 12.42%. Its return on capital employed (ROCE) is 11.68%.
Is CLBT a good stock to buy?
This page provides a data-driven analysis of Cellebrite DI Ltd. (CLBT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.